research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
Search
for
Sort by
Research
870-900 / 1000+ results
research Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia
iL-PRF treatment improves hair growth for androgenetic alopecia.
research Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis
Dupilumab for skin problems might reactivate hair loss in some patients.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research 1116 Novel androgen receptor degrader for androgenetic alopecia (AGA) application
A new treatment for hair loss shows promise with fewer side effects.
research Single-stage transplantation combined with epidermal stem cells promotes the survival of tissue-engineered skin by inducing early angiogenesis
Epidermal stem cells improve skin graft survival by promoting early blood vessel formation.
research Effects of Retinoic Acid on Wingless (WNT) Signaling in the Hair Follicles of Mice
Inhibiting retinoic acid activates WNT signaling, potentially aiding hair disorder and skin cancer treatments.
research 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration
Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Successful treatment of alopecia totalis with tofacitinib in a Danish patient
A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
research LB1159 First-in-human clinical trial evaluating AI-09, a novel long-lasting ready-to-use liquid injectable neuromodulator for the treatment of glabellar lines
AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
An 11-year-old girl with severe hair loss regrew and repigmented her hair after JAK inhibitor treatment.
research Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research Ativo para tratamento de alopecia androgenética disponibilizados por diferentes marcas
The document concluded that home treatments are needed for hair loss control, but professionals should better understand how these treatments work.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Modified platelet rich plasma therapy for alopecia totalis
The combined treatment helps improve severe hair loss and reduces the need for other medications.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Concentrated Growth Factor from Autologous Platelet Promotes Hair Growth in Androgenetic Alopecia
CGF from platelets helps hair regrowth in people with androgenetic alopecia.
research Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk
Skin tumor regression is helped by retinoic acid signaling blocking Wnt signaling.
research Blocking α1‐integrin reverts the adhesive phenotype of adult fibroblasts towards a foetal‐like migratory phenotype
Blocking α1-integrin makes adult fibroblasts more like foetal ones, improving their movement and aiding wound healing.
research [Genetic expression and morphogenesis of the skin in vertebrates].
Retinoic acid can change skin structures in vertebrates, like turning scales into feathers or hair buds into glands.
research Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Autologous Platelet‐Rich Plasma Efficacy in the Field of Regenerative Medicine: Product and Quality Control
PRP treatments need standardization for consistent results.
research Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis
A new engineered treatment shows promise in curing heart fibrosis.
research Expression of TGF Beta Receptor 1 in Sika Deer Antler
TGF-β receptor 1 helps deer antlers grow by aiding skin and cartilage cell growth.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.